1. Home
  2. HTLD vs CSTL Comparison

HTLD vs CSTL Comparison

Compare HTLD & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartland Express Inc.

HTLD

Heartland Express Inc.

HOLD

Current Price

$8.02

Market Cap

595.3M

Sector

Industrials

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$39.13

Market Cap

661.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTLD
CSTL
Founded
1978
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
595.3M
661.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
HTLD
CSTL
Price
$8.02
$39.13
Analyst Decision
Sell
Strong Buy
Analyst Count
4
6
Target Price
$8.75
$38.67
AVG Volume (30 Days)
517.0K
573.2K
Earning Date
10-31-2025
11-03-2025
Dividend Yield
1.00%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$868,930,000.00
$343,530,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
10.15
52 Week Low
$7.00
$14.59
52 Week High
$12.78
$40.61

Technical Indicators

Market Signals
Indicator
HTLD
CSTL
Relative Strength Index (RSI) 58.46 76.91
Support Level $7.00 $33.03
Resistance Level $8.00 $40.61
Average True Range (ATR) 0.21 1.49
MACD 0.09 0.21
Stochastic Oscillator 90.85 78.50

Price Performance

Historical Comparison
HTLD
CSTL

About HTLD Heartland Express Inc.

Heartland Express Inc is engaged in providing truckload services across the United States, Mexico, and Canada. These truckload services are asset-based transportation services in the dry van truckload market. The company offers truckload temperature-controlled transportation services, and Mexico logistics services. A majority of its customers represent the consumer goods, appliances, food products, and automotive industries.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Share on Social Networks: